EUCTR2007-001269-14-IT进行中（未招募）不适用
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir versus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine Resistant Chronic Hepatitis B Virus Infection. - ND
BRISTOL-M.SQUIBB0 个研究点目标入组 84 人开始时间: 2008年7月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •) Signed Written Informed Consent 2) Subjects with chronic HBV infection (detectable HBsAg at screening and for at least 24 weeks prior to screening, or detectable HBsAg for < 24 weeks and negative for IgM core antibody); subjects may be either HBeAg-positive or HBeAg-negative; 3) Subjects must have a history of previous lamivudine treatment, must have LVD resistance substitutions at reverse transcriptase rtM204I/V ± rtL180M, documented by INNO-Lipa HBV-DR assay, and must be receiving lamivudine at the screening visit; 4) Subjects must have compensated liver function and must meet ALL of the following criteria; International Normalization Ratio (INR) ≤ 1.5 Serum albumin ≥ 3 g/dL (≥ 30 g/L) Serum total bilirubin ≤ 2.5 mg/dL (≤ 42.75 μmol/L) 5) HBV DNA ≥ 172,000 IU/mL HBV DNA (approximately 106 copies/mL) by PCR at screening; 6) ALT >1.0 x and ≤10 x the ULN at screening and at least once ≥ 12 weeks prior to screening with no value falling within the normal reference range in the intervening period; 7) Men and women, ≥ 18 years of age (or minimum age of consent in a given country)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •) WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 6 weeks after the last dose of investigational product. 2) Evidence of decompensated cirrhosis including but not limited to: variceal bleeding; hepatic encephalopathy; or ascites requiring management with diuretics or paracentesis; 3) Coinfection with HIV, hepatitis C virus ([HCV]; coinfection is defined as HCV Ab-positive with detectable HCV ribonucleic acid [RNA] by PCR), or hepatitis D virus (HDV). 4) Recent history of pancreatitis (within 24 weeks prior to the first dose of study medication); 5) Currently abusing illegal drugs or alcohol sufficient in the Investigator?s opinion, to prevent adequate compliance with study therapy or to increase the risk of hepatotoxicity or pancreatitis; 6) Other serious medical conditions that might preclude completion of this study or that require chronic administration of prohibited medications (see Exclusion Criteria 13 - 15). 7) Renal impairment that precludes subject from tolerating the per protocol study drug dose levels (see Protocol section 5.3.1). 8) Serum creatinine > 1.5 mg/dL; 9) Hemoglobin < 10.0 g/dL; 10) Platelet count < 70,000/mm3; 11) Absolute neutrophil count < 1500 cells/mm3; 12) Serum alpha fetoprotein (AFP) level > 100 ng/mL. 13) Known history of allergy to nucleoside or nucleotide analogues. 14) Except lamivudine, any prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B (e.g., adefovir, entecavir, famciclovir, tenofovir/emtricitabine, clevudine); 15) Therapy with interferon, thymosin alpha or other immuno-stimulators within 24 weeks of randomization into this study; 16) Required chronic administration of medications which cause immunosuppression or which are associated with a high risk of nephrotoxicity or hepatotoxicity or which affect renal excretion. (See Protocol Section 5.5.1 for examples.). 17) Prisoners or subjects who are involuntarily incarcerated; 18) Subject who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease); 19) Unable to tolerate oral medication; 20) Poor peripheral venous access; 21) Off lamivudine therapy for greater than 7 days between the time of the screening visit and initiation of study treatment.
研究者
相似试验
进行中（未招募）
1 期
A Phase III Study of the Safety and Efficacy or Entecavir in Pediatric Patients with Chronic HBV-InfectioCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 14.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-016357-17-BEBristol-Myers Squibb International Corporation180
已完成
3 期
Comparative study in childrens with chronic Hepatitis B virus infection who are HBeAg positive.CTRI/2011/09/002001The pharmaceutical company sponsoring this study is BristolMyers Squibb180
进行中（未招募）
1 期
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) versus Placebo in Pediatric Subjects with Chronic Hepatitis B Virus (HBV) Infection who are HBeAg-PositiveCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 12.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2009-016357-17-GRBristol-Myers Squibb International Corporation257
进行中（未招募）
不适用
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovirversus Adefovir Added to Continuing Lamivudine in Adults with Lamivudine ResistantChronic Hepatitis B Virus Infection. Revised Protocol 02, incorporating protocol amendment 01 (v1.0, Date 03-Jan-2008), protocol amendment 02 (v1.0, Date 31-Jul-2008) and Administrative Letter 01 (Date 06-Jun-2008).HEPATITIS B VIRUSMedDRA version: 9.1Level: LLTClassification code 10008910Term: Chronic hepatitis BEUCTR2007-001269-14-DEBristol-Myers Squibb International Corporation105
进行中（未招募）
1 期
A Phase III Study of the Safety and Efficacy or Entecavir in Pediatric Patients with Chronic HBV-InfectioCHRONIC HEPATITIS B VIRUS,PEDIATRICMedDRA version: 14.1Level: PTClassification code 10008910Term: Chronic hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-016357-17-DEBristol-Myers Squibb International Corporation180